Currently, assessing the severity and progression of symptoms in a patient diagnosed with Alzheimer's disease involves in-clinic monitoring and testing of the patient every 6 to 12 months. However, monitoring and testing a patient more frequently is preferred, but increasing the frequency of in-clinic monitoring and testing can be costly and inconvenient to the patient. Thus, assessing the severity and progression of symptoms via remote monitoring and testing of the patient outside of a clinic environment as described herein provides advantages in cost, ease of monitoring, ecological validity, reliability and convenience to the patient, like improvement of quality of life. Systems, methods and devices according to the present disclosure provide a diagnostic for assessing one or more pre-clinical signs and/or symptoms of Alzheimer's disease in a patient by passive monitoring of the patient and/or active testing of the patient.

According to an aspect, there is provided a computer-implemented method for determining an indication of visual attention/motoric dysfunction of a subject and/or an indication of executive cognitive dysfunction of the subject during or following a test comprising a plurality of targets that are to be completed by the subject, the method comprising the steps of receiving information on the time taken to complete each of the plurality of targets by the subject; determining a regression line for the subject based on the received information on the time taken to complete each of the plurality of targets and information on the time taken to complete each of the plurality of targets for a reference group of subjects; determining an indication of visual attention/motoric dysfunction of the subject based on a slope of the determined regression line and/or an indication of executive cognitive dysfunction of the subject based on an offset of the determined regression line; and outputting the indication of the visual attention/motoric dysfunction of the subject and/or the indication of the executive cognitive dysfunction of the subject.

The present invention discloses indicator fluids, reference indicator fluid, and usage thereof, and systems and methods for assessing movement of molecular substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a human cranio-spinal cavity. Indicator fluid moving from the cerebrospinal fluid compartment enables measurements of levels of indicator fluid in blood or urine and assessment of the cranio-spinal cavity's ability to remove molecular substances. The indicator fluids may be contrast agents used for imaging, such as by computed tomography imaging, and magnetic resonance imaging, or imaging utilizing radioactive substances by positron emission tomography, single-photon emission computed tomography or scintigraphy. Using these imaging modalities, the invention describes indicator fluids, systems and methods enabling assessment of movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity, and from the human cranio-spinal cavity to lymphatic pathways or kidneys.

A timeclock control system includes a client electronic device configured to administer an alertness test to a user. A timeclock controller is coupled to and configured to be actuated by the client electronic device.

A cognitive function evaluation device includes an acquisition unit that acquires body motion data representing a body motion of a person to be evaluated during walking; a calculation unit that calculates a displacement of a body of the person to be evaluated during walking based on the acquired body motion data; and an evaluation unit that evaluates a cognitive function of the person to be evaluated based on a frequency peak representing a cycle of walking of person-to-be-evaluated obtained by performing a frequency analysis on the calculated displacement, and to output the evaluation result.

Disclosed are methods for quantification of a perivascular space in a subject's central nervous system. The methods include administering contrast agent into cerebrospinal fluid of the subject; performing quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI) on a region of interest of the subject's brain; and determining presence of the contrast agent in the perivascular space within the region of interest.

A computer-implemented method includes obtaining movement data associated with a subject and measured by a stationary motion sensor. The movement data includes a series of values representing a series of movement events of the subject crossing fields of view of the stationary motion sensor. Each movement event in the series of movement events is associated with a respective time stamp. The computer-implemented method further includes extracting a plurality of features from the movement data, determining that the movement data is consistent with symptoms of an illness using a machine-learning model and based upon the plurality of features, and generating an output indicating a result of the determination.

Systems, methods, and computer readable media for determining cognitive impairment (CI) in patients are provided herein. Various regional structural-functional parameters of the retina can serve as biomarkers for the detection of CI. The method can include forming a database including a quantification of retinal structure and retinal function of a plurality of eyes associated with a plurality of patients, providing a baseline cognitive impairment (CI) reference. The method can include determining a measure of functionality of neurons in the retina based on an electroretinogram (ERG) of a patient. The method can include determining a structural measure of the first retina based on a generalized dimension spectrum and singularity spectrum of the skeletonized retinal image, and a lacunarity parameter of the skeletonized retinal image. The method can include determining a level of cognitive impairment based on the structural and functional measures.

The medical information display apparatus includes an image acquisition unit that acquires a first brain image which is a brain image of a subject captured at a first time point and a second brain image captured at a second time point later in time than the first time point, a registration unit that performs registration between the first and the second brain image, an image analysis unit that extracts a first cavity region and a second cavity region from the first brain image and the second brain image, respectively, a display unit, and a display controller displays, a cavity expansion part included in a first non-cavity region, which is a region other than the first cavity region, and included in the second cavity region in a distinguishable manner from a region other than the cavity expansion part from a result of the registration between the first and second brain image.

An evaluation device includes a display unit; a point-of-gaze detector configured to detect a position of a point of gaze of a subject on the display unit; a display controller configured to display, on the display unit, an image containing an induction area that tends to induce visual hallucinations in the subject; a determination unit configured to, based on position data on the point of gaze, determine whether the point of gaze is staying; an area detector configured to, when the determination unit determines that the point of gaze is staying, calculate an area of staying in which the point of gaze is staying in the display unit; an acquisition unit configured to acquire a feature value representing a state of display of the area of staying that is calculated by the area setting unit; and an evaluation unit.